chlorambucil has been researched along with Scleroderma, Systemic in 16 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement." | 2.66 | Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. ( Clements, P; Duann, S; Furst, DE; Gong, H; Greenwald, GI; Simmons, M; Tashkin, DP, 1987) |
| "Pyomyositis has become an increasingly recognized disease in temperate climates." | 2.37 | Pyomyositis in a patient with progressive systemic sclerosis. Case report and review of the literature. ( Baum, S; Minor, RL; Schulze-Delrieu, KS, 1988) |
| "In a study of 48 patients with systemic sclerosis (SSc)." | 1.28 | Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. ( Agopian, MS; Clements, PJ; Furst, DE; Peter, JB; Telian, NS, 1990) |
| " Although hematologic malignancies have been known to develop consequent to long-term use of alkylating agents, and bone marrow suppression is well known, acute myelofibrosis has not, to our knowledge, been reported as a complication of this therapy, nor has any specific myeloproliferative syndrome been described consequent to such therapy in a patient with PSS." | 1.26 | Acute myelofibrosis in progressive systemic sclerosis. Report of a case developing during long term chlorambucil therapy and discussion of pathogenetic factors. ( Chung, KB; Gisser, SD, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (87.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clements, P | 2 |
| Lachenbruch, P | 1 |
| Furst, D | 1 |
| Paulus, H | 1 |
| Olszewska, Z | 2 |
| Gisser, SD | 1 |
| Chung, KB | 1 |
| Dudek, H | 1 |
| Ansell, BM | 1 |
| Nasseh, GA | 1 |
| Bywaters, EG | 1 |
| Clements, PJ | 2 |
| Peter, JB | 1 |
| Agopian, MS | 1 |
| Telian, NS | 1 |
| Furst, DE | 3 |
| Hillis, S | 1 |
| Lachenbruch, PA | 1 |
| Miller, BL | 1 |
| Sterz, MG | 1 |
| Paulus, HE | 1 |
| Moreland, L | 1 |
| Alarcón, GS | 1 |
| Minor, RL | 1 |
| Baum, S | 1 |
| Schulze-Delrieu, KS | 1 |
| Greenwald, GI | 1 |
| Tashkin, DP | 1 |
| Gong, H | 1 |
| Simmons, M | 1 |
| Duann, S | 1 |
| Delespesse, G | 1 |
| Kennes, B | 1 |
| Duchateau, J | 1 |
| Dryll, A | 1 |
| Rousselet, F | 1 |
| Ryckewaert, A | 1 |
| Kahn, MF | 1 |
| Duguet, M | 1 |
| de Sèze, S | 1 |
| Marmont, A | 1 |
| Rossi, F | 1 |
| Bordo, D | 1 |
| Saporta, L | 1 |
| Godeau, P | 1 |
| Delrieu, F | 1 |
| Delbarre, F | 1 |
| Kostanecki, W | 1 |
| Mazurkiewicz, W | 1 |
| Górkiewicz, A | 1 |
| Zborzil, J | 1 |
| Cruchaud, A | 1 |
2 reviews available for chlorambucil and Scleroderma, Systemic
| Article | Year |
|---|---|
Pyomyositis in a patient with progressive systemic sclerosis. Case report and review of the literature.
Topics: Chlorambucil; Female; Humans; Middle Aged; Myositis; Scleroderma, Systemic; Streptococcal Infections | 1988 |
[Auto-immune diseases and immunodepressive therapy. II. Current clinical indications].
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Arteritis; Autoimmune | 1974 |
5 trials available for chlorambucil and Scleroderma, Systemic
| Article | Year |
|---|---|
The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo.
Topics: Adult; Chlorambucil; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; S | 1993 |
[Immediate results of long-term treatment of systemic scleroderma with leukeran].
Topics: Adult; Aged; Chlorambucil; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; H | 1978 |
Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.
Topics: Chlorambucil; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Immunosuppressive Agent | 1989 |
Comment on the article by Furst et al.
Topics: Chlorambucil; Clinical Trials as Topic; Humans; Immunosuppression Therapy; Research Design; Sclerode | 1989 |
Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study.
Topics: Adult; Chlorambucil; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Lung; Male; Midd | 1987 |
9 other studies available for chlorambucil and Scleroderma, Systemic
| Article | Year |
|---|---|
Acute myelofibrosis in progressive systemic sclerosis. Report of a case developing during long term chlorambucil therapy and discussion of pathogenetic factors.
Topics: Acute Disease; Adult; Bone Marrow; Cell Division; Chlorambucil; Female; Fibroblasts; Hematopoietic S | 1979 |
[Effect of leukeran on iron, copper, transferrin and ceruloplasmin levels in blood serum in systemic scleroderma after long-term treatment].
Topics: Adult; Aged; Ceruloplasmin; Chlorambucil; Copper; Female; Humans; Iron; Male; Middle Aged; Scleroder | 1979 |
Scleroderma in childhood.
Topics: Adolescent; Age Factors; Arthritis, Juvenile; Bone Diseases; Child; Chlorambucil; Diagnosis, Differe | 1976 |
Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
Topics: Adult; beta 2-Microglobulin; Biopterins; Chlorambucil; Cytokines; Female; Humans; Interleukin-2; Mal | 1990 |
[Inflammatory rheumatisms and paraproteins excepting myeloma and Waldenström's disease. Study of 18 personal cases of this association].
Topics: Adult; Aged; Arthritis; Arthritis, Rheumatoid; Blood Protein Disorders; Chlorambucil; Electrophoresi | 1969 |
[Current aspects of immunosuppressive therapy of collagen diseases].
Topics: Arthritis, Rheumatoid; Asparaginase; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi | 1973 |
[Generalized scleroderma. Treatment with immunosuppressive agents].
Topics: Adult; Azathioprine; Chlorambucil; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Male; | 1972 |
[Hair changes in immunosuppressive therapy].
Topics: Antineoplastic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Hair; Humans; Immunosuppression | 1971 |
[Immunosuppressive treatment of collagen diseases].
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Collagen Diseases; Cyclophosphamide; Dermatomyosi | 1969 |